Brighton Jones LLC Takes $351,000 Position in IDEXX Laboratories, Inc. $IDXX

Brighton Jones LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 654 shares of the company’s stock, valued at approximately $351,000.

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Mutual of America Capital Management LLC raised its stake in IDEXX Laboratories by 79.6% during the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after purchasing an additional 8,609 shares during the period. Plato Investment Management Ltd grew its holdings in shares of IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after purchasing an additional 835 shares during the period. Genesis Wealth Advisors LLC purchased a new position in IDEXX Laboratories in the second quarter valued at approximately $215,000. ORG Wealth Partners LLC purchased a new position in IDEXX Laboratories in the second quarter valued at approximately $273,000. Finally, Symmetry Partners LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $266,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the sale, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director M Anne Szostak sold 2,187 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Leerink Partners raised their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research note on Monday, August 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. UBS Group assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price objective for the company. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $628.54 on Friday. The firm has a market cap of $50.28 billion, a price-to-earnings ratio of 52.33, a PEG ratio of 4.06 and a beta of 1.58. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $638.21 and its two-hundred day moving average is $565.90. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.